GLSHQ (Gelesis Holdings) Inventories, Work In Process: $4.43 Mil (As of Jun. 2023)


What is Gelesis Holdings Inventories, Work In Process?

Gelesis Holdings GLSHQ -99.00% Inventories, Work In Process is $4.43 Mil as of Jun. 2023.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Gelesis Holdings's work in process for the quarter that ended in Jun. 2023 was $4.43 Mil.

Gelesis Holdings Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for Gelesis Holdings's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gelesis Holdings Inventories, Work In Process Chart

Gelesis Holdings Annual Data
Trend Dec21 Dec22
Inventories, Work In Process
2.64 4.70

Gelesis Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.75 4.47 4.70 4.36 4.43

Gelesis Holdings Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of $4.43 Mil mean?
Gelesis Holdings (GLSHQ) has a Inventories, Work In Process of $4.43 Mil as of Jun. 2023. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Gelesis Holdings and its competitors.
Is Gelesis Holdings' Inventories, Work In Process too high?
Gelesis Holdings' current Inventories, Work In Process is $4.43 Mil.
How does Gelesis Holdings' Inventories, Work In Process compare to RBSH and PPCB?
Gelesis Holdings' Inventories, Work In Process of $4.43 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Biotechnology company?
A good Inventories, Work In Process depends on the Biotechnology industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Gelesis Holdings and its competitors. Gelesis Holdings's current Inventories, Work In Process is $4.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gelesis Holdings stock overvalued right now?
Gelesis Holdings (GLSHQ) has a current Inventories, Work In Process of $4.43 Mil. The current Inventories, Work In Process is $4.43 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For Gelesis Holdings (GLSHQ), the current Inventories, Work In Process is $4.43 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gelesis Holdings Business Description

Address 501 Boylston Street, Suite 6102, Boston, MA, USA, 02116
Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.